磺脲类药物对体重的影响以及临床应用的注意事项  

Effects of Sulfonylureas on Body Weight and Its Clinical Application

作　　者：闾倩[1] 石勇铨[1] LU Qian;SHI Yong-quan(Department of Endocrinology, Shanghai Changzheng Hospital, Shanghai 200003, China)

机构地区：[1]上海长征医院内分泌科,上海200003

出　　处：《药品评价》2017年第3期32-35,共4页Drug Evaluation

摘　　要：磺脲类降糖药物的使用已有60余年的历史,其降糖效果明确,在临床实践中被广泛使用。但是磺脲类药物具有体重增加等不良反应,多数的2型糖尿病患者伴有肥胖或超重,而体重的增加会加重胰岛素抵抗以及增加心血管不良事件的发生,因此,磺脲类药物引起的体重变化越来越受关注。生活方式干预,选择合适的降糖药物如二甲双胍、胰高血糖素样肽-1(glucagon-like peptide-1,GLP-1)类似物、钠-葡萄糖协同转运蛋白-2(sodium-glucose co-transporter-2,SGLT-2)抑制剂等联合治疗可减少磺脲类药物对于体重的影响,且降糖效果良好。Sulphonylureas are oral anti-diabetic drugs(OADs)that were introduced more than60years ago,and its hypoglycemic effect is clear.Clinicians are familiar with their use and they remain extensively used.However,the sulphonylureas class is associated with adverse effects of weight gain and hypoglycaemia.Most of the patients with type2diabetes are associated with obesity or overweight,weight gain may increase insulin resistance and increase the occurrence of adverse cardiovascular events,and therefore we pay more attention to weight in the sulfonylureas treatment.Lifestyle intervention,choosing the appropriate drugs such as metformin,glucagon-like peptide analogues and sodium glucose co-transporter inhibitors as combination drug may mitigate the adverse effects of weight gain,and achieve excellent hypoglycemic effect.

关 键 词：2型糖尿病 磺脲类药物 体重 

分 类 号：R977.15[医药卫生—药品]